Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 3/20 | 0.57 |
| ▸ | CDK1 | P06493 | 1/20 | 0.52 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.51 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.51 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.51 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.51 |
| ▸ | TK2 | O00142 | 4/20 | 0.50 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.49 |
| ▸ | TYMP | P19971 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL40665 | 1.00 | PYGM (0.57) | PYGMCDK1SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL18871260 | 1.00 | PYGM (0.57) | PYGMCDK1SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL28817 | 1.00 | PYGM (0.57) | PYGMCDK1SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL29754 | 1.00 | PYGM (0.57) | PYGMCDK1SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL15810706 | 1.00 | PYGM (0.57) | PYGMCDK1SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL17210997 | 1.00 | PYGM (0.57) | PYGMCDK1SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL5091966 | 0.90 | TK2 (0.47) | PYGMCDK1TK2TYMP | |
| SCHEMBL20830476 | 0.90 | PYGM (0.45) | PYGMCDK1TK2P2RY2 | |
| SCHEMBL12642176 | 0.89 | CDA (0.48) | PYGMCDK1TK2TYMP | |
| SCHEMBL22460365 | 0.89 | CDA (0.48) | PYGMCDK1TK2TYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3871696-B1 | LIPID FORMULATIONS FOR DELIVERY OF MESSENGER RNA | TRANSLATE BIO INC (US) | 2025-03-19 | — | — | EP | claimed |
| EP-3641834-B1 | MESSENGER RNA THERAPY FOR THE TREATMENT OF FRIEDREICH'S ATAXIA | TRANSLATE BIO INC (US) | 2023-10-04 | — | — | EP | claimed |
| EP-3160959-B1 | STEREOCHEMICALLY ENRICHED COMPOSITIONS FOR DELIVERY OF NUCLEIC ACIDS | TRANSLATE BIO INC (US) | 2023-08-30 | — | — | EP | claimed |
| EP-3501605-B1 | MRNA THERAPY FOR ARGININOSUCCINATE SYNTHETASE DEFICIENCY | TRANSLATE BIO INC (US) | 2023-06-28 | — | — | EP | claimed |
| EP-3587409-B1 | BIODEGRADABLE LIPIDS FOR DELIVERY OF NUCLEIC ACIDS | TRANSLATE BIO INC (US) | 2022-06-01 | — | — | EP | claimed |
| EP-3459549-B1 | SELECTIVE ANTISENSE COMPOUNDS AND USES THEREOF | IONIS PHARMACEUTICALS INC (US) | 2022-04-06 | — | — | EP | claimed |
| EP-3270894-B1 | MRNA THERAPY FOR POMPE DISEASE | TRANSLATE BIO INC (US) | 2021-02-24 | — | — | EP | claimed |
| EP-3060257-B1 | LIPID FORMULATIONS FOR DELIVERY OF MESSENGER RNA | TRANSLATE BIO INC (US) | 2021-02-24 | — | — | EP | claimed |
| EP-3226912-B1 | MESSENGER RNA THERAPY FOR TREATMENT OF ARTICULAR DISEASE | TRANSLATE BIO INC (US) | 2021-01-20 | — | — | EP | claimed |
| EP-3469074-B1 | MESSENGER RNA THERAPY FOR THE TREATMENT OF ORNITHINE TRANSCARBAMYLASE DEFICIENCY | TRANSLATE BIO INC (US) | 2020-12-09 | — | — | EP | claimed |
| EP-3350343-B1 | METHODS AND COMPOSITIONS FOR GENOMIC TARGET ENRICHMENT AND SELECTIVE DNA SEQUENCING | PETAOMICS INC (US) | 2020-04-22 | — | — | EP | claimed |
| EP-3148552-B1 | BIODEGRADABLE LIPIDS FOR DELIVERY OF NUCLEIC ACIDS | TRANSLATE BIO INC (US) | 2019-07-31 | — | — | EP | claimed |
| EP-3060303-B1 | MRNA THERAPY FOR ARGININOSUCCINATE SYNTHETASE DEFICIENCY | TRANSLATE BIO INC (US) | 2018-11-14 | — | — | EP | claimed |
| EP-3122878-B1 | MRNA THERAPY FOR THE TREATMENT OF OCULAR DISEASES | TRANSLATE BIO INC (US) | 2018-10-24 | — | — | EP | claimed |
| EP-2906256-B1 | SELECTIVE ANTISENSE COMPOUNDS AND USES THEREOF | IONIS PHARMACEUTICALS INC (US) | 2018-08-22 | — | — | EP | claimed |
| EP-2742056-B1 | SELECTIVE ANTISENSE COMPOUNDS AND USES THEREOF | IONIS PHARMACEUTICALS INC (US) | 2017-01-11 | — | — | EP | claimed |
| EP-1025120-B1 | METHODS, KITS AND COMPOSITIONS PERTAINING TO PNA MOLECULAR BEACONS | BOSTON PROBES INC (US) | 2010-08-18 | — | — | EP | claimed |
| EP-1225234-B1 | A method for sequencing nucleic acids | AGILENT TECHNOLOGIES INC (US) | 2007-11-07 | — | — | EP | claimed |
| EP-1027372-B1 | METHODS, KITS AND COMPOSITIONS PERTAINING TO LINEAR BEACONS | BOSTON PROBES INC (US) | 2004-12-29 | — | — | EP | claimed |
| US-20190255194-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNATX INC (US) | 2019-08-22 | — | — | US | disclosed |
| EP-2931319-B1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNATX INC (US) | 2019-08-21 | — | — | EP | disclosed |
| US-20170136132-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2017-05-18 | — | — | US | disclosed |
| EP-2918275-B1 | Alternative nucleic acid molecules and uses thereof | MODERNA THERAPEUTICS INC (US) | 2016-05-18 | — | — | EP | disclosed |
| EP-2918275-A1 | Alternative nucleic acid molecules and uses thereof | Roy, Atanu (US) | 2015-09-16 | — | — | EP | disclosed |
| US-20110130440-A1 | NON-NATURAL RIBONUCLEOTIDES, AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-06-02 | — | — | US | disclosed |
| US-20110098215-A1 | PEPTIDES AND METHODS OF USE AS THERAPEUTICS AND SCREENING AGENTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-04-28 | — | — | US | disclosed |
| US-20110098215-A1 | PEPTIDES AND METHODS OF USE AS THERAPEUTICS AND SCREENING AGENTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170136132-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | PYGM 2038/4885CDK1 4204/4885SLC28A1 317/4885 |
| US-20190255194-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | PYGM 2038/4885CDK1 4204/4885SLC28A1 317/4885 |
| US-20110130440-A1 | NON-NATURAL RIBONUCLEOTIDES, AND METHODS OF USE THEREOF | NSUN2, RNMT, RNGTT | PYGM 1491/4885CDK1 2855/4885SLC28A1 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.